High Content Imaging Services

×

Explore the Power of High Content Imaging

High content imaging (HCI) and analysis of 3D in vitro models, such as organoids and spheroid cultures, provide invaluable information that gives researchers greater insights into complex disease pathophysiology for more effective assessment of novel compounds and new therapeutic modalities.

Crown Bioscience offers a suite of powerful 3D in vitro imaging-based assays that recapitulate and quantify complex human biology in a robust and high-throughput imaging platform.

These HCI assays are ideal for testing compounds for oncology, immuno-oncology, inflammation, and cystopathy indications. Coupled with our growing organoid biobank of PDX-derived organoid (PDXO) tumor models and patient-derived organoids (PDO), our 3D in vitro high content imaging services enable you to discover the full therapeutic potential of your compounds and new modalities.

Key advantages include:

• High content 3D imaging for phenotypic evaluation of response to treatment in a customizable and scalable 384-well format
• 3D image analysis with highly specialized high content imaging analysis software designed to measure >500 phenotypic changes induced by your compound of interest
• Reliable, reproducible data provides clinically relevant information on compound effects to support important decisions throughout your drug discovery and development workflow— and test multiple drug combination strategies simultaneously
• Physiologically relevant 3D in vitro environments. Services are available for Crown Bioscience’s extensive biobank of well-characterized PDXO and PDO models with patient data. 3D spheroid models from CDX and PDX material are also available

Learn more about our HCI Services for high-throughput compound screening, immuno-oncology, and cystopathic diseases.